China and Medical AI

Implications of Big Biodata for the Bioeconomy

Caroline Schuerger

Vikram Venkatram

Katherine Quinn

May 2024

Medical artificial intelligence, which depends on large repositories of biological data, can improve public health and contribute to the growing global bioeconomy. Countries that strategically prioritize medical AI could benefit from a competitive advantage and set global norms. This report examines China’s stated goals for medical AI, finding that the country’s strategy for biodata collection and medical AI development positions it to be an economic and technological leader in this sector.

Download Full Report

Related Content

As the U.S. government considers banning genomics companies from China in the Biosecure Act, it opens a broader question of how the U.S. and other market economies should deal with China’s national champions. This blog… Read More

Steph Batalis, Caroline Schuerger and Vikram Venkatram explore three notable areas in the life sciences where LLMs are catalyzing meaningful advances: drug discovery, genetics, and precision medicine. Read More

Data Brief

China’s Industrial Clusters

June 2022

China is banking on applying AI to biotechnology research in order to transform itself into a “biotech superpower.” In pursuit of that goal, it has emphasized bringing together different aspects of the development cycle to… Read More